The KOASTAL-1 study enrolled 383 adult patients with MDD. Navacaprant was shown to be safe and generally well-tolerated with ...

Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...

Neuroscience company Neumora Therapeutics (NMRA) announced today that its experimental treatment for depression, Navacaprant, ...

The biotech reported data from KOASTAL-1, the first of three phase 3 trials of navacaprant in major depressive disorder.

Neumora Therapeutics Inc.’s stock tumbled 80% Thursday, after the clinical-stage biotech said a late-stage trial of a ...

Navacaprant is an highly selective kappa opioid receptor antagonist expected to modulate reward processing pathways and mediate depressive states.

BofA analyst Geoff Meacham lowered the firm’s price target on Neumora Therapeutics (NMRA) to $7 from $22 and keeps a Buy rating on the shares.

The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...

Massachusetts, USA-based based brain disease biotech Neumora Therapeutics shares tumbled 81.4% to 1.97 after it revealed that ...

Neumora Therapeutics (NMRA) announced results from the Phase 3 KOASTAL-1 Study of navacaprant for the treatment of major depressive disorder. The KOASTAL-1 Study is the first of three replicate Phase ...

Shares of Neumora Therapeutics, Inc. (NMRA) are down more than 80% at $1.81 in premarket trading Thursday, following the release of ...

Neumora Therapeutics ( NMRA) shares crashed 80% to an all-time low Thursday when the biopharmaceutical firm announced that a ...